Press Releases Clinuvel Pharmaceuticals Limited

Equities

Market Closed - Australian S.E. Other stock markets 02:11:00 2024-05-14 am EDT			5-day change	1st Jan Change
15.62 ^AUD	+3.03%		+4.13%	-2.38%

Apr. 29	Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%	MT
Mar. 14	Clinuvel Pharmaceuticals Launches Share Buyback Program	MT

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors	Mar. 28	AQ
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine	Mar. 04	AQ
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care	23-02-28	AQ
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings	23-02-23	AQ
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals	23-02-01	AQ
CLINUVEL Trial Results Show Drug Reduces DNA Damage	23-01-15	AQ
Clinuvel Pharmaceuticals : Appendix 4C & Activity Report	22-07-24	PU
Clinuvel Pharmaceuticals : Change of Director’s Interest Notice	22-06-23	PU
Clinuvel Pharmaceuticals : Change of Director’s Interest Notice	22-06-14	PU
Clinuvel Pharmaceuticals : H.C. Wainwright Global Investment Conference Presentation	22-05-26	PU
Clinuvel Pharmaceuticals : H.C. Wainwright Global Investment Conference 2022	22-05-25	PU
Clinuvel Pharmaceuticals : Notice of change of interests of initial substantial holder	22-05-24	PU
Clinuvel Pharmaceuticals : Notice of initial substantial holder	22-05-19	PU
CLINUVEL progresses vitiligo treatment program	22-05-09	AQ
Positive final results in stroke	22-05-03	AQ
Letter to shareholders from CLINUVEL’s CEO	22-04-29	AQ
Clinuvel Pharmaceuticals : CEO letter	22-04-28	PU
Clinuvel Pharmaceuticals : Quarterly Activities/Appendix 4C Cash Flow Report	22-04-27	PU
Clinuvel Pharmaceuticals : Appendix 4C & Activity Report	22-04-27	PU
Clinuvel Pharmaceuticals : Notice of ceasing to be a substantial holder	22-04-26	PU

No results for this search